{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:23:24Z","timestamp":1791487404432,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pmed.1005030","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000}}],"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1193955"],"award-info":[{"award-number":["GNT1193955"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) is a highly effective biomedical intervention for the prevention of HIV acquisition. There is a strong interest among communities and policymakers for LAI-PrEP scale-up, accelerating the demand for clear guidance on testing approaches that balance accuracy with scalability. Unlike oral pre-exposure prophylaxis, LAI-PrEP may overcome adherence challenges, such as difficulty with frequent clinic visits. However, LAI-PrEP results in prolonged subtherapeutic drug levels after discontinuation, which can increase the risk of drug resistance among those who have an undetected HIV infection. This systematic review evaluates how different HIV testing strategies, including rapid diagnostic tests (RDTs), laboratory-based immunoassays and nucleic acid testing (NAT), affect clinical utility and programme delivery of LAI-PrEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We searched databases and retrieved studies up to April 8, 2025, and supplemented findings with data collected through a World Health Organization (WHO) survey among ongoing and completed LAI-PrEP implementation studies. We included publications reporting original or primary data on clinical, diagnostic and resource-use outcomes of HIV testing for LAI-PrEP. Meta-analyses were conducted using random-effects models. Chi-square tests were used to examine differences between related outcomes. Certainty of evidence was determined using the GRADE methodology (Prospero: CRD42024605562). Risk Of Bias In Non-randomised Studies of Interventions, Version 2 (ROBINS-I V2) assessment tool was used to assess bias for non-randomised comparative studies. Of 7,698 records identified, 38 reports representing 22 studies (cabotegravir: 20, lenacapavir: 2) across 15 countries were included. The overall certainty of evidence was low. Most were observational cohorts (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) or non-randomised comparator studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). Among 8,171 LAI-PrEP users in four randomised controlled trials, HIV detection rates were similar across strategies (9\/8171 (RDT) versus 14\/8171 (NAT) (Odds ratio (OR) 0.66 (95% confidence interval: 0.29\u20131.50;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.87)), with no difference in adverse events. Compared with laboratory-based tests, RDTs enabled faster turnaround (same-day versus up to 7 days), more rapid treatment initiation (1 day versus 6\u20139 days), and lower test costs (US$4 versus US$22). All tests had similar negative predictive value (~100%) at LAI-PrEP initiation and comparable positive predictive value (~55%) at continuation. There was little difference in delayed HIV detection (11\/8171 (RDT) versus 0\/8171 (NAT)). In the HPTN 083 trial, NAT use was occasionally associated with false-positive results, leading to unnecessary PrEP holds or discontinuation (7\/2483). NAT might have detected HIV before resistance emerged, though no prospective or modelling evidence showed clinical benefit at a population level. There was limited evidence of HIV self-testing for LAI-PrEP delivery. We noted that our assessment of performance accuracy in different testing strategies may introduce selection bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RDT-based testing strategies have comparable accuracy to laboratory-based strategies and are more accessible and scalable, which can ensure that testing does not become a barrier to accessing or continuing LAI-PrEP. As countries expand access to LAI-PrEP amid increasingly constrained resources, adoption of new WHO guidance supporting the use of RDTs can enable simpler, more affordable, and user-centred HIV testing approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1005030","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:46:11Z","timestamp":1776361571000},"page":"e1005030","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-9262","authenticated-orcid":true,"given":"Warittha","family":"Tieosapjaroen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5499-5523","authenticated-orcid":true,"given":"Cheryl C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2782-4184","authenticated-orcid":true,"given":"Carlota","family":"Baptista Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-7843","authenticated-orcid":true,"given":"Magdalena","family":"Barr-DiChiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rodolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8714-8889","authenticated-orcid":true,"given":"Heather Leigh","family":"Ingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-6407","authenticated-orcid":true,"given":"Heather-Marie A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Prochazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busi","family":"Msimanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-7742","authenticated-orcid":true,"given":"Celine","family":"Lastrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1264-7893","authenticated-orcid":true,"given":"Hortensia","family":"Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2254-1823","authenticated-orcid":true,"given":"Lastone","family":"Chitembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"Andifasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-1698","authenticated-orcid":true,"given":"Nandi","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-714X","authenticated-orcid":true,"given":"Raphael J.","family":"Landovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-7403","authenticated-orcid":true,"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"pmed.1005030.ref001","unstructured":"World Health Organization. Consolidated guideline on differentiated HIV testing services. Geneva, Switzerland: World Health Organization; [cited 2025 Mar 31]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240096394"},{"key":"pmed.1005030.ref002","unstructured":"World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: provider module for oral and long-acting PrEP. [cited 2025 Mar 31]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/378164\/9789240097230-eng.pdf?sequence=1"},{"key":"pmed.1005030.ref003","unstructured":"World Health Organization. Long-acting injectable cabotegravir for HIV prevention. 2022 [cited 2025 Mar 31]. Available from: http:\/\/who.int\/publications\/i\/item\/9789240054097"},{"issue":"7","key":"pmed.1005030.ref004","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"RJ Landovitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"pmed.1005030.ref005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"L-G Bekker","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"pmed.1005030.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309811","article-title":"Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084","volume":"19","author":"EE Tolley","year":"2024","journal-title":"PLoS One"},{"issue":"10337","key":"pmed.1005030.ref007","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"S Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"13","key":"pmed.1005030.ref008","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"CF Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"pmed.1005030.ref009","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global AIDS monitoring. 2025 [cited 2025 Mar 31]. Available from: http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/global-aids-monitoring_en.pdf"},{"key":"pmed.1005030.ref010","unstructured":"World Health Organization. Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct results and connection 2015. 2015 [cited 2025 Mar 31]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK316024\/"},{"issue":"6","key":"pmed.1005030.ref011","article-title":"Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP","volume":"68","author":"K Han","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"pmed.1005030.ref012","unstructured":"U.S. Centre of Disease Control and Prevention. HIV nexus: CDC resources for clinicians. [cited 2025 Mar 31]. Available from: https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/index.html"},{"issue":"7","key":"pmed.1005030.ref013","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"RT Gandhi","year":"2025","journal-title":"JAMA"},{"key":"pmed.1005030.ref014","article-title":"Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition","author":"L Lorenzetti","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"pmed.1005030.ref015","volume-title":"WHO handbook for guideline development","author":"World Health Organization","year":"2014","edition":"2"},{"key":"pmed.1005030.ref016","author":"J Higgins","journal-title":"Cochrane handbook for systematic reviews of interventions version 6.5"},{"key":"pmed.1005030.ref017","unstructured":"Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). [cited 2025 Mar 31]. Available from: https:\/\/www.prisma-statement.org\/"},{"key":"pmed.1005030.ref018","unstructured":"Cochrane Methods. Risk of Bias 2 (RoB 2) tool. [cited 2025 Mar 31]. Available from: https:\/\/methods.cochrane.org\/risk-bias-2"},{"issue":"8","key":"pmed.1005030.ref019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"PF Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7650","key":"pmed.1005030.ref020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"GH Guyatt","year":"2008","journal-title":"BMJ"},{"key":"pmed.1005030.ref021","unstructured":"GRADE Handbook. Introduction to GRADE Handbook Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013 October."},{"issue":"4","key":"pmed.1005030.ref022","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40273-023-01342-y","article-title":"Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States","volume":"42","author":"AJ Brogan","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"pmed.1005030.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00251-X","article-title":"Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis","volume":"9","author":"L Jamieson","year":"2022","journal-title":"Lancet HIV"},{"issue":"10","key":"pmed.1005030.ref024","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/infdis\/jiv523","article-title":"Potential clinical and economic value of long-acting preexposure prophylaxis for south african women at high-risk for HIV infection","volume":"213","author":"RP Walensky","year":"2016","journal-title":"J Infect Dis"},{"key":"pmed.1005030.ref025","article-title":"Costs of implementing long-acting injectable cabotegravir as HIV prophylaxis in Brazil","volume":"33","author":"J Paranhos","year":"2023","journal-title":"Physis"},{"issue":"3","key":"pmed.1005030.ref026","article-title":"Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study","volume":"11","author":"SN Cox","year":"2024","journal-title":"Lancet HIV"},{"issue":"4","key":"pmed.1005030.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00365-4","article-title":"Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study","volume":"10","author":"J Smith","year":"2023","journal-title":"Lancet HIV"},{"issue":"9","key":"pmed.1005030.ref028","article-title":"First case of HIV seroconversion with integrase resistance mutations on long-acting cabotegravir for prevention in routine care","volume":"11","author":"CA Koss","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"pmed.1005030.ref029","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/QAD.0000000000003644","article-title":"Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis","volume":"37","author":"A Hazra","year":"2023","journal-title":"AIDS"},{"key":"pmed.1005030.ref030","unstructured":"World Health Organization survey on HIV testing for CAB-LA PrEP programs\/research. 2024."},{"key":"pmed.1005030.ref031","unstructured":"Landovitz RJ, Gao F, Fogel JM, Hanscom B, Clement M, Tran HV, et al. Performance characteristics of HIV RNA screening with CAB-LA PrEP in HPTN 083. AIDS2024; Munich, Germany; 2024."},{"issue":"12","key":"pmed.1005030.ref032","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/infdis\/jiac415","article-title":"HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention","volume":"226","author":"SH Eshleman","year":"2022","journal-title":"J Infect Dis"},{"issue":"8","key":"pmed.1005030.ref033","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00307-24","article-title":"Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis","volume":"12","author":"JM Fogel","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"12","key":"pmed.1005030.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00251-X","article-title":"Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis","volume":"9","author":"L Jamieson","year":"2022","journal-title":"Lancet HIV"},{"issue":"12","key":"pmed.1005030.ref035","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00261-8","article-title":"Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial","volume":"10","author":"RJ Landovitz","year":"2023","journal-title":"Lancet HIV"},{"issue":"2","key":"pmed.1005030.ref036","first-page":"66","article-title":"The levi syndrome: characteristics of early HIV infection with cabotegravir for PrEP","volume":"31","author":"SH Eshleman","year":"2023","journal-title":"Top Antivir Med"},{"issue":"9","key":"pmed.1005030.ref037","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"224","author":"MA Marzinke","year":"2021","journal-title":"J Infect Dis"},{"issue":"4","key":"pmed.1005030.ref038","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/M21-1548","article-title":"Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States\u00a0: a cost-effectiveness analysis","volume":"175","author":"AM Neilan","year":"2022","journal-title":"Ann Intern Med"},{"issue":"6","key":"pmed.1005030.ref039","article-title":"EE281 cost-effectiveness of every two month cabotegravir long-acting (CAB-LA) for pre-exposure prophylaxis (PREP) compared with daily oral tenofovir disoproxil fumarate (TDF)\/emtricitabine (FTC) as prep to prevent HIV-1 in the UK","volume":"27","author":"P O\u2019Brien","year":"2024","journal-title":"Value Health"},{"key":"pmed.1005030.ref040","unstructured":"Macdonald P. Use of HIV rapid detection tests when initiating long-acting cabotegravir for HIV prevention, within an implementation science project. HIVR4P2024."},{"issue":"10","key":"pmed.1005030.ref041","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","article-title":"Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention: HPTN 084","volume":"225","author":"SH Eshleman","year":"2022","journal-title":"J Infect Dis"},{"issue":"4","key":"pmed.1005030.ref042","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00053-23","article-title":"Extended analysis of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"67","author":"MA Marzinke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"pmed.1005030.ref043","article-title":"Performance characteristics of HIV RNA screening with CAB-LA PrEP in HPTN 083","author":"R Landovitz","year":"2024","journal-title":"AIDS"},{"key":"pmed.1005030.ref044","unstructured":"Parikh UM, Altamirano J, Safa H, Hazra A, Shukla P, Hedberg T. Early virologic success on ART following breakthrough infection on CAB-LA PrEP. HIVR4P2024; Lima, Peru."},{"issue":"11","key":"pmed.1005030.ref045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(24)00235-2","article-title":"Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension","volume":"11","author":"MR Kamya","year":"2024","journal-title":"Lancet HIV"},{"issue":"5","key":"pmed.1005030.ref046","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae254","article-title":"High rates of missed HIV testing among oral PrEP users in the United States from 2018-2021: a national assessment on compliance with HIV testing recommendations of the CDC PrEP guidelines","volume":"11","author":"J Baron","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"pmed.1005030.ref047","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00029-2","article-title":"Cost-effectiveness of point-of-care versus centralised, laboratory-based nucleic acid testing for diagnosis of HIV in infants: a systematic review of modelling studies","volume":"10","author":"SM le Roux","year":"2023","journal-title":"Lancet HIV"},{"issue":"10","key":"pmed.1005030.ref048","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/bios10100133","article-title":"Point of care diagnostics in resource-limited settings: a review of the present and future of PoC in its most needed environment","volume":"10","author":"B Heidt","year":"2020","journal-title":"Biosensors"},{"key":"pmed.1005030.ref049","article-title":"Suboptimal laboratory testing at PrEP initiation in the United States, 2022-2023","author":"W Zhu","year":"2025","journal-title":"Aids"},{"key":"pmed.1005030.ref050","article-title":"Should antigen-antibody rapid diagnostic tests be used to detect acute HIV infection? A systematic review and meta-analysis of diagnostic performance","author":"E Fajardo","year":"2025","journal-title":"medRxiv"},{"key":"pmed.1005030.ref051","article-title":"The detection and management of early HIV infection: a clinical and public health emergency","author":"MK Smith","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"pmed.1005030.ref052","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection","volume":"17","author":"EW Fiebig","year":"2003","journal-title":"AIDS"},{"issue":"10400","key":"pmed.1005030.ref053","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","article-title":"The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review","volume":"402","author":"LN Broyles","year":"2023","journal-title":"Lancet"},{"key":"pmed.1005030.ref054","author":"D Van de Vijver","year":"2025","journal-title":"Evaluating HIV testing strategies to reduce drug resistance during CAB-LA rollout in Thailand: a modelling study. Presented at: 13th IAS Conference on HIV Science (IAS 2025); Abstract C3"},{"issue":"11","key":"pmed.1005030.ref055","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1172\/JCI138099","article-title":"HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus","volume":"130","author":"EK Halvas","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"pmed.1005030.ref056","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","article-title":"Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis","volume":"43","author":"S Palmer","year":"2005","journal-title":"J Clin Microbiol"},{"key":"pmed.1005030.ref057","unstructured":"Vijver D, Kampen J v, Wongsa A, Janamnuaysook R, Mesplede T, Matrajt L, et al. OAC0205 evaluating HIV testing strategies to reduce drug resistance during CAB-LA rollout in Thailand. International AIDS Society, Kigali, Rwanda & Virtual; 2025."},{"issue":"2","key":"pmed.1005030.ref058","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10461-017-1707-8","article-title":"A global review of HIV self-testing: themes and implications","volume":"22","author":"DR Stevens","year":"2018","journal-title":"AIDS Behav"},{"issue":"5","key":"pmed.1005030.ref059","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1473-3099(11)70368-1","article-title":"Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis","volume":"12","author":"N Pant Pai","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"pmed.1005030.ref060","doi-asserted-by":"crossref","first-page":"108273","DOI":"10.1016\/j.ijid.2025.108273","article-title":"Mental health, stigma and risk perception among early adopters of HIV PrEP with LA Cabotegravir in Italy: a multicenter cross-sectional and implementation study","volume":"163","author":"G Del Duca","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pmed.1005030.ref061","article-title":"Resistance analyses of lenacapavir, emtricitabine\/tenofovir alafenamide and emtricitabine\/tenofovir disoproxil fumarate in the PURPOSE 1 and 2 studies","volume":"233","author":"S Cox","year":"2026","journal-title":"J Infect Dis"},{"issue":"4","key":"pmed.1005030.ref062","article-title":"Real-world HIV RNA and antigen\/antibody testing among people who use long-acting injectable preexposure prophylaxis","volume":"81","author":"W Zhu","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pmed.1005030.ref063","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s13063-025-09138-5","article-title":"Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN)","volume":"26","author":"S Kusemererwa","year":"2025","journal-title":"Trials"},{"issue":"10","key":"pmed.1005030.ref064","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(25)00169-9","article-title":"Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysis","volume":"12","author":"AN Phillips","year":"2025","journal-title":"Lancet HIV"},{"issue":"3","key":"pmed.1005030.ref065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/OLQ.0000000000002272","article-title":"Patterns and correlates of initiation of long-acting injectable cabotegravir for preexposure prophylaxis: a case-control analysis","volume":"53","author":"R Rossotti","year":"2026","journal-title":"Sex Transm Dis"},{"key":"pmed.1005030.ref066","unstructured":"Vijver DVd, Kampen JV, Janamnuaysook R, Mesplede T, Matrajt L, Moore M. Impact of rapid HIV testing and self-testing on lenacapavir effectiveness and resistance in Thailand. CROI2026"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1005030","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:48:49Z","timestamp":1776880129000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005030"}},"subtitle":[],"editor":[{"given":"Matthias","family":"Egger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1005030","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}